Trial Profile

A Phase II, Multicenter, Open, Basket Study of AB-106 to Treat the Subjects With Local Progression or Systemic Metastasis Solid Tumors With NTRK Gene Fusion

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Taletrectinib (Primary)
Indications Solid tumours
Focus Therapeutic Use
Sponsors AnHeart Therapeutics

Most Recent Events

10 Apr 2024 According to a Nuvation Bio media release, AnHeart Therapeutics has been acquired by Nuvation Bio and AnHeart is now a wholly-owned subsidiary of Nuvation Bio.
18 Jun 2021 Status changed from not yet recruiting to recruiting.
17 Jun 2021 According to an AnHeart Therapeutics media release, the first patient has been dosed in the study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com